附子理中汤治疗腹泻型肠易激综合征的疗效观察
|
摘要
目的探究附子理中汤对腹泻型肠易激综合征的临床疗效及对血清中炎症因子的影响。方法选择2016年5月至2018年4月期间接收的120例腹泻型肠易激综合患者为研究对象,按随机数字表法将研究对象随机分为对照组和治疗组,每组60例。对照组给予匹维溴铵,治疗组给予附子理中汤。对比两组治疗后的总有效率,对比两组治疗前后的IBS生活质量评分、SF-36生活质量评分以及血清中C反应蛋白(C-reactive protein,CRP)、肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)和白细胞介素-6(Interleukin-6,IL-6)水平。结果治疗组总有效率优于对照组(P <0. 05);两组患者治疗后的IBS生活质量评分和SF-36生活质量评分均优于治疗前,治疗组治疗后IBS生活质量评分和SF-36生活质量评分优于对照组(P <0. 05);两组治疗后血清中CRP、TNF-α和IL-6水平均低于治疗前,治疗后治疗组血清中CRP、TNF-α和IL-6水平均低于对照组(P <0. 05)。结论附子理中汤治疗腹泻型肠易激综合征的临床疗效显著,改善患者的炎症反应效果更理想。
Objective To study the clinical efficacy of diarrhea predominant irritable bowel syndrome treated with Fuzi Lizhong Decoction and its effect on serum inflammatory factors. Methods From May 2016 to April 2018,120 patients with diarrhea-predominant irritable bowel syndrome were randomly divided into control group and treatment group with 60 cases in each group. The control group was treated with P-bromide,and the treatment group was given with Fuzi Lizhong Decoction. The total effective rate of the two groups after treatment was compared. The IBS quality of life score,SF-36 quality of life score,and serum levels of C-reactive protein( CRP),tumor necrosis factor-alpha( TNF-alpha) and interleukin-6( IL-6) were compared between the two groups before and after treatment. Results The total effective rate of treatment group was significantly higher than that of the control group( P < 0. 05). The scores of IBS quality of life and SF-36 quality of life after treatment in both groups were significantly higher than those before treatment. The scores of IBS quality of life and SF-36 quality of life in the treatment group were significantly higher than those in the control group after treatment( P < 0. 05). The serum levels of CRP,TNF-a and IL-6 in both groups were significantly lower than those before treatment. The serum levels of CRP,TNF-a and IL-6 in the treatment group were significantly lower than those in the control group after treatment( P < 0. 05). Conclusions Fuzi Lizhong Decoction have significant clinical effects on diarrhea-predominant irritable bowel syndrome,and the effect of improving inflammation is better.
Objective To study the clinical efficacy of diarrhea predominant irritable bowel syndrome treated with Fuzi Lizhong Decoction and its effect on serum inflammatory factors. Methods From May 2016 to April 2018,120 patients with diarrhea-predominant irritable bowel syndrome were randomly divided into control group and treatment group with 60 cases in each group. The control group was treated with P-bromide,and the treatment group was given with Fuzi Lizhong Decoction. The total effective rate of the two groups after treatment was compared. The IBS quality of life score,SF-36 quality of life score,and serum levels of C-reactive protein( CRP),tumor necrosis factor-alpha( TNF-alpha) and interleukin-6( IL-6) were compared between the two groups before and after treatment. Results The total effective rate of treatment group was significantly higher than that of the control group( P < 0. 05). The scores of IBS quality of life and SF-36 quality of life after treatment in both groups were significantly higher than those before treatment. The scores of IBS quality of life and SF-36 quality of life in the treatment group were significantly higher than those in the control group after treatment( P < 0. 05). The serum levels of CRP,TNF-a and IL-6 in both groups were significantly lower than those before treatment. The serum levels of CRP,TNF-a and IL-6 in the treatment group were significantly lower than those in the control group after treatment( P < 0. 05). Conclusions Fuzi Lizhong Decoction have significant clinical effects on diarrhea-predominant irritable bowel syndrome,and the effect of improving inflammation is better.
引文
[1]李晓青,常敏,许东,等.中国肠易激综合征流行病学调查现状分析[J].胃肠病学和肝病学杂志,2013,22(8):734-739.
[2]李军祥,陈誩,唐旭东,等.肠易激综合征中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(3):227-232.
[3]邓振华,常江.肠易激综合征的治疗进展[J].世界华人消化杂志,2016,24(19):3009-3017.
[4]陈婷,唐旭东,王凤云,等.腹泻型肠易激综合征中医辨证的源流及发展趋势[J].中华中医药杂志,2015,30(8):2671-2674.
[5]顾文.穴位敷贴联合针刺治疗肠易激综合征的临床观察及对脑肠肽5-HT和炎症因子IL-8的影响[J].中国中西医结合消化杂志,2018,26(3):261-263,269.
[6]中华医学会消化病学分会胃肠动力学组.肠易激综合征诊断和治疗的共识意见[J].中华消化杂志,2008,28(1):38-40.
[7]中华中医药学会脾胃病分会.肠易激综合征中医诊疗共识意见[J].中华中医药杂志,2010,25(7):1062-1064.
[8]时昭红,刘凡,杨家耀,等.中医病证结合治疗腹泻型肠易激综合征有效性的临床研究[J].时珍国医国药,2017,28(10):2437-2439.
[9]李跃文,王瑞明.基于中医传承辅助平台的中医药治疗肠易激综合征的组方规律分析[J].中华中医药学刊,2017,35(10):2676-2678.
[10]张丹丹.腹泻型肠易激综合征主要症状和鞣酸苦参碱胶囊治疗评估[J].中国社区医师,2017,33(27):74,76.
[11]蔡伦,胡玉英,陆永经,等.柴胡疏肝汤对炎症诱导的肠易激综合征大鼠HPA轴亢进及内脏高敏的影响[J].中药药理与临床,2017,33(6):17-21.
[12]张霞,蒋欢欢,赵汉清,等.益生菌联合针灸对腹泻型肠易激综合征患者炎症因子的影响[J].山西医药杂志,2016,45(18):2150-2152.
[13]黄小平,刘欣,王燕,等.肠易激综合征酪酪肽表达及其与炎症因子相关性研究[J].中国实用内科杂志,2016,36(2):153-154.
[14]卢文生,蒋钦云,陆永经,等.柴胡疏肝散对肠易激综合征大鼠血清IL-6、TNF-α和5-HT的影响[J].内蒙古中医药,2013,32(25):1-2.
[15]谭立军.肠易激综合征患者CRP水平及其与幽门螺杆菌感染的相关性[J].中国热带医学,2013,13(9):1143-1145.
[2]李军祥,陈誩,唐旭东,等.肠易激综合征中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(3):227-232.
[3]邓振华,常江.肠易激综合征的治疗进展[J].世界华人消化杂志,2016,24(19):3009-3017.
[4]陈婷,唐旭东,王凤云,等.腹泻型肠易激综合征中医辨证的源流及发展趋势[J].中华中医药杂志,2015,30(8):2671-2674.
[5]顾文.穴位敷贴联合针刺治疗肠易激综合征的临床观察及对脑肠肽5-HT和炎症因子IL-8的影响[J].中国中西医结合消化杂志,2018,26(3):261-263,269.
[6]中华医学会消化病学分会胃肠动力学组.肠易激综合征诊断和治疗的共识意见[J].中华消化杂志,2008,28(1):38-40.
[7]中华中医药学会脾胃病分会.肠易激综合征中医诊疗共识意见[J].中华中医药杂志,2010,25(7):1062-1064.
[8]时昭红,刘凡,杨家耀,等.中医病证结合治疗腹泻型肠易激综合征有效性的临床研究[J].时珍国医国药,2017,28(10):2437-2439.
[9]李跃文,王瑞明.基于中医传承辅助平台的中医药治疗肠易激综合征的组方规律分析[J].中华中医药学刊,2017,35(10):2676-2678.
[10]张丹丹.腹泻型肠易激综合征主要症状和鞣酸苦参碱胶囊治疗评估[J].中国社区医师,2017,33(27):74,76.
[11]蔡伦,胡玉英,陆永经,等.柴胡疏肝汤对炎症诱导的肠易激综合征大鼠HPA轴亢进及内脏高敏的影响[J].中药药理与临床,2017,33(6):17-21.
[12]张霞,蒋欢欢,赵汉清,等.益生菌联合针灸对腹泻型肠易激综合征患者炎症因子的影响[J].山西医药杂志,2016,45(18):2150-2152.
[13]黄小平,刘欣,王燕,等.肠易激综合征酪酪肽表达及其与炎症因子相关性研究[J].中国实用内科杂志,2016,36(2):153-154.
[14]卢文生,蒋钦云,陆永经,等.柴胡疏肝散对肠易激综合征大鼠血清IL-6、TNF-α和5-HT的影响[J].内蒙古中医药,2013,32(25):1-2.
[15]谭立军.肠易激综合征患者CRP水平及其与幽门螺杆菌感染的相关性[J].中国热带医学,2013,13(9):1143-1145.